A Study to Evaluate Concomitant Perfluorohexyloctane Use With Contact Lens Wear
← catalyst calendarSponsored by Bausch & Lomb Incorporated (industry) · BLCO — their whole pipeline →.
Phase
Phase 4
Status
Completed
Study type
Interventional
Design
Na · None · Basic science
Enrollment
104actual
Sites
6
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-07-02 | actual | When the study began enrolling |
| Primary completion | 2025-11-03 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-11-03 | actual | The whole study's end, after follow-up |
| First posted | 2025-07-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Dry Eye
Intervention
- Drug: Perfluorohexyloctane ophthalmic solution
Primary outcome
what the primary-completion date above is the date OFChange from baseline (CFB) in CLDEQ-8 score at Visit 4
measured Assessed for approximately 30 days
Permalink · BLCO's whole pipeline · Catalyst calendar · Every registered study · What changed